Welcome to our dedicated page for Aspire Biopharma Holdings news (Ticker: ASBP), a resource for investors and traders seeking the latest updates and insights on Aspire Biopharma Holdings stock.
Aspire Biopharma Holdings, Inc. (Nasdaq: ASBP) is a biotechnology and biopharmaceutical company centered on a patent-pending sublingual delivery platform for drugs and supplements. The ASBP news feed on Stock Titan aggregates coverage of the company’s clinical, regulatory, commercial and capital markets developments, giving readers a focused view of how Aspire’s strategy is progressing over time.
Company press releases describe a lead program in fast-acting, high-dose sublingual aspirin (OTASA) for the emergency treatment of suspected acute myocardial infarction, supported by pilot clinical data and FDA pre‑IND feedback under a 505(b)(2) pathway. News items also cover Aspire’s broader pipeline plans, which include reformulating approved drugs such as erectile dysfunction medications and semaglutide using its sublingual technology.
Beyond pharmaceuticals, Aspire Biopharma reports commercial activities around BUZZ BOMB™, a proprietary sublingual caffeine supplement marketed through its Buzz Bomb Caffeine Company LC subsidiary. News updates highlight product launches, manufacturing scale-up, e‑commerce initiatives, sampling campaigns and brand partnerships with high‑profile endurance athletes.
Investors following ASBP news can also track key corporate events disclosed by the company, such as Nasdaq listing compliance matters, reverse stock split decisions, patent filings, additions to the scientific team and participation in industry conferences like CPHI Frankfurt and virtual equity events. Together, these updates offer insight into Aspire Biopharma’s efforts to advance its sublingual platform, secure partnerships, expand consumer offerings and manage its public listing and financing arrangements. Bookmark this page to review new ASBP headlines, official announcements and related market commentary in one place.
Aspire Biopharma (Nasdaq:ASBP) reported a major brand boost for its wholly owned Buzz Bomb Caffeine Company after sponsoring elite runner Ashley Paulson at the 2026 Jackpot Ultra Running Festival.
Key points: Buzz Bomb content surpassed 400,000 views in 48 hours, and Paulson set a new women's 100-mile world record of 12:19:34, with the company citing increased online revenue and consumer acquisition.
Aspire Biopharma (NASDAQ:ASBP) regained full compliance with Nasdaq continued listing requirements on February 20, 2026.
The company met the $2.5 million minimum stockholders' equity requirement under Listing Rule 5550(b)(1) and earlier met the $1.00 minimum bid requirement under Rule 5550(a)(2). Nasdaq confirmed the matter is closed, but Aspire will remain under a Panel Monitor through February 18, 2027.
Aspire Biopharma (NASDAQ:ASBP) announced on February 19, 2026 that its subsidiary BUZZ BOMB™ Caffeine Company named ChicExecs as its public relations agency of record as it pursues brand expansion, product innovation, and a comprehensive brand refresh.
ChicExecs will lead media relations, events, strategic partnerships, and PR campaigns to position BUZZ BOMB™—a 50mg sublingual caffeine powder in single-serving stick packs—across food, beverage, fitness, and lifestyle channels.
Aspire Biopharma (NASDAQ:ASBP) filed a provisional patent application for a proprietary sublingual powder formulation of meclizine on February 17, 2026. The formulation targets rapid-onset relief, aiming to cut typical oral onset from about 60 minutes to minutes and to support a 505(b)(2) regulatory path.
The company cites ~4.09 million U.S. prescriptions in 2023 and a $450M global meclizine market, projecting growth to $650M by 2032.
Aspire Biopharma (Nasdaq: ASBP) appointed Phillip Balatsos to its Board of Directors, effective February 6, 2026, following the planned departures of Suren Ajjarapu and Donald G. Fell.
Balatsos brings 25+ years of capital markets and entrepreneurial experience and will serve on the Audit and Compensation Committees, supporting Aspire's strategy to reformulate established drugs using its patent-pending sublingual delivery platform.
Aspire Biopharma (Nasdaq:ASBP) filed a provisional USPTO patent application on February 12, 2026 for a sublingual powder formulation of ondansetron, aimed at rapid relief of chemotherapy-, radiation- and surgery-induced nausea.
The company highlights potential near-instant absorption versus 30-minute oral tablets, plans to pursue an FDA 505(b)(2) pathway, and cites >12.5 million U.S. prescriptions and a ~$1.4B global market (2023).
Aspire Biopharma (Nasdaq:ASBP) entered a securities purchase agreement to sell up to 26,250 Series A convertible preferred shares at $800 per share for aggregate gross proceeds of up to $21.0 million. An initial closing on February 6, 2026 issued 13,750 shares for $11.0 million.
Proceeds will repay legacy indebtedness, support operations and strategic initiatives, and are expected to help the company regain compliance with Nasdaq stockholders' equity requirements. A second closing is subject to customary conditions. RBW Capital Partners acted as sole placement agent.
Aspire Biopharma (Nasdaq: ASBP) regained compliance with Nasdaq Listing Rule 5550(a)(2) after achieving a closing bid of at least $1.00 per share for 10 consecutive business days, and Nasdaq confirmed the matter is closed on February 10, 2026.
The company remains subject to an extension to evidence compliance with the $2.5 million stockholders' equity requirement and says it has made progress on strategic plans for 2026 with additional details to follow.
Aspire Biopharma (NASDAQ:ASBP) subsidiary Buzz Bomb Caffeine Company will showcase its flagship BUZZ BOMB™ sublingual caffeine at The Sports & Active Nutrition Summit USA in San Diego on February 18-20, 2026. The product delivers a rapid 50mg caffeine dose via single-serving stick packs in four flavors and features new branding and a redesigned mobile website for direct purchase.
Aspire Biopharma (Nasdaq:ASBP) subsidiary Buzz Bomb Caffeine Company signed a strategic brand management and distribution agreement with Blue Shark Beverages, effective February 1, 2026, to expand BUZZ BOMB™ retail placement across Southern California.
The rollout debuts in Palm Springs and Coachella Valley, then phases into Los Angeles and San Diego, targeting resorts, hotels, casinos, festival channels and broader retail outlets.